SCHEMBL7799996

SCHEMBL7799996

CCCCc1ccc(C(=O)O)c(OC)c1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.89
PPARG P37231 1/20 0.89
AGTR1 P30556 1/20 0.58
AGTR2 P50052 1/20 0.58
KAT8 Q9H7Z6 2/20 0.54
ALDH1A1 P00352 3/20 0.53
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C8 P10632 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
CYP2C19 P33261 1/20 0.50
RARB P10826 4/20 0.49
RARA P10276 1/20 0.49
RARG P13631 1/20 0.49
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31065733 0.94 PPARA (1.00) PPARAPPARGAGTR1AGTR2KAT8
SCHEMBL3298521 0.94 PPARA (1.00) PPARAPPARGAGTR1AGTR2KAT8
SCHEMBL20504238 0.94 PPARA (1.00) PPARAPPARGAGTR1AGTR2KAT8
SCHEMBL3963370 0.90 PPARA (0.78) PPARAPPARGAGTR1AGTR2ALDH1A1
SCHEMBL14398158 0.88 PPARA (0.69) PPARAPPARGKAT8ALDH1A1CYP1A2
SCHEMBL7801348 0.86 PPARG (0.68) PPARAPPARGCYP1A2CYP3A4CYP2C8
SCHEMBL5501065 0.83 PPARG (0.68) PPARAPPARGAGTR1AGTR2ALDH1A1
SCHEMBL27481259 0.83 PPARG (0.67) PPARAPPARGAGTR1AGTR2ALDH1A1
SCHEMBL11461004 0.83 PPARG (0.67) PPARAPPARGALDH1A1CYP1A2CYP3A4
SCHEMBL4160316 0.82 PPARA (0.63) PPARAPPARGAGTR1AGTR2KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 US disclosed
US-6110934-A Substituted benzamide derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2000-08-29 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed
EP-0906283-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-04-07 EP disclosed
WO-1997048683-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1997-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A PPARA 2232/4885PPARG 1448/4885AGTR1 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.